These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19702644)

  • 1. A single dose of intravenous esomeprazole decreases gastric secretion in healthy volunteers.
    Nichita C; Abdou AE; Maerten P; Herranz M; Mouret N; Thalmann C; Michetti PF; Dorta G
    Aliment Pharmacol Ther; 2009 Nov; 30(10):1022-9. PubMed ID: 19702644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
    Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
    Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults.
    Hartmann D; Eickhoff A; Damian U; Riemann JF; Schilling D
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):133-7. PubMed ID: 17272998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers.
    Hunt RH; Armstrong D; James C; Chowdhury SK; Yuan Y; Fiorentini P; Taccoen A; Cohen P
    Am J Gastroenterol; 2005 Sep; 100(9):1949-56. PubMed ID: 16128938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole.
    Goldstein JL; Miner PB; Schlesinger PK; Liu S; Silberg DG
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1189-96. PubMed ID: 16611280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.
    Junghard O; Hassan-Alin M; Hasselgren G
    Eur J Clin Pharmacol; 2002 Oct; 58(7):453-8. PubMed ID: 12389067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study.
    Wilder-Smith CH; Röhss K; Bondarov P; Hallerbäck B; Svedberg LE; Ahlbom H
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1099-104. PubMed ID: 15569112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study.
    Miehlke S; Madisch A; Kirsch C; Lindner F; Kuhlisch E; Laass M; Knoth H; Morgner A; Labenz J
    Aliment Pharmacol Ther; 2005 Apr; 21(8):963-7. PubMed ID: 15813831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acid control with esomeprazole and lansoprazole: a comparative dose-response study.
    Wilder-Smith C; Lind T; Lundin C; Nauclér E; Nilsson-Pieschl C; Röhss K
    Scand J Gastroenterol; 2007 Feb; 42(2):157-64. PubMed ID: 17327934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers.
    Galmiche JP; Bruley Des Varannes S; Ducrotté P; Sacher-Huvelin S; Vavasseur F; Taccoen A; Fiorentini P; Homerin M
    Aliment Pharmacol Ther; 2004 Mar; 19(6):655-62. PubMed ID: 15023167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial.
    Spechler SJ; Sharma P; Traxler B; Levine D; Falk GW
    Am J Gastroenterol; 2006 Sep; 101(9):1964-71. PubMed ID: 16848802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects.
    Hunt RH; Armstrong D; Yaghoobi M; James C
    Aliment Pharmacol Ther; 2010 Mar; 31(6):648-57. PubMed ID: 20015104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intravenous esomeprazole 40 mg and pantoprazole 40 mg on intragastric pH in healthy subjects. A prospective, open, randomised, two-way cross-over comparative study.
    Piccoli F; Ory G; Hadengue A; Beglinger C; Degen L
    Arzneimittelforschung; 2007; 57(10):654-8. PubMed ID: 18074759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous esomeprazole pharmacodynamics in critically ill patients.
    Metz DC; Fulda GJ; Olsen KM; Monyak JT; Simonson SG; Sostek MB
    Curr Med Res Opin; 2010 May; 26(5):1141-8. PubMed ID: 20230209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, Phase I study in healthy volunteers.
    Miner P; Plachetka J; Orlemans E; Fort JG; Sostek M
    Aliment Pharmacol Ther; 2010 Aug; 32(3):414-24. PubMed ID: 20491746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of dose and timing of esomeprazole administration on 24-h, daytime and night-time acid inhibition in healthy volunteers.
    Wilder-Smith C; Röhss K; Bokelund Singh S; Sagar M; Nagy P
    Aliment Pharmacol Ther; 2010 Nov; 32(10):1249-56. PubMed ID: 20955444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough.
    Hammer J; Schmidt B
    Aliment Pharmacol Ther; 2004 May; 19(10):1105-10. PubMed ID: 15142200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers.
    Galmiche JP; Sacher-Huvelin S; Bruley des Varannes S; Vavasseur F; Taccoen A; Fiorentini P; Homerin M
    Aliment Pharmacol Ther; 2005 Mar; 21(5):575-82. PubMed ID: 15740541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease.
    Johnson DA; Stacy T; Ryan M; Wootton T; Willis J; Hornbuckle K; Brooks W; Doviak M
    Aliment Pharmacol Ther; 2005 Jul; 22(2):129-34. PubMed ID: 16011671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral buffered esomeprazole is superior to i.v. pantoprazole for rapid rise of intragastric pH: a wireless pH metry analysis.
    Banerjee R; Reddy DN; Guda NM; Kalpala R; Mahurkar S; Darisetty S; Rao GV
    J Gastroenterol Hepatol; 2010 Jan; 25(1):43-7. PubMed ID: 19874444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.